

Learning Objectives

After completing this activity, the participant should be better able to:

- Review the data supporting the classification of RA by the ACR/EULAR and ACR updated treatment guidelines
- Utilize strategies to diagnose and identify RA patients who may benefit from early disease-suppressing therapy
- Identify current disease-modifying anti-rheumatic drugs (DMARDs) and newer combination and biological therapies to delay disease progression and improve outcomes in patients with RA
- Identify the role of biosimilars in the treatment of early stage rheumatoid arthritis
- Utilize algorithm for evaluation and implementation of treatment strategies to identify psoriatic arthritis patients who may benefit from early disease-suppressing therapy
- Identify newer biological therapies to delay disease progression and improve outcomes in patients with psoriatic arthritis
- Identify evolving concepts of spondyloarthritis and update on treatment options
- Identify the key components that contribute to the pathogenesis of knee osteoarthritis
- Discuss current clinical data and outcomes associated with the use of chondroitin sulfate, glucosamine and hyaluronic acid in osteoarthritis treatment
- Evaluate strategies to prevent increased cardiovascular risk in patients with rheumatoid arthritis
- Identify strategies to alleviate chronic widespread pain due to central sensitization in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis